Key Collaborations Coupled with Product Launches are Expected to Drive the Global Vaso Occlusive Crisis Associated with Sickle Cell Disease Market

Published: Mar 2022

Global vaso occlusive crisis associated with sickle cell disease market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028).  The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in September 2019, the US Government and Gates Foundation have pledged $200 million to bring gene therapy to patients with sickle diseases. The collaboration between the National Institute of Health (NIH) and the Gates Foundation aimed at ensuring effective, safe, and durable gene-based therapy cures in the US and relevant countries in sub-Saharan Africa. 

Browse the full report description of “Global Vaso Occlusive crisis Associated with Sickle Cell Disease Market Size, Share & Trends Report by Type (Crizanlizumab, SGD-2083, NVX-508, PF-04447943, and Others) and by Application (Hospital, Clinics, and Others) Forecast( 2022-2028)” at https://www.omrglobal.com/industry-reports/vegan-pet-food-market

Moreover, in 2020, according to the National Institute of Health, the US Food and Drug Administration, pharmaceutical companies and non-profit organizations have partnered to accelerate the development of gene-based therapies for 30 million Americans who suffer from a rare disease. Product launches and approvals are expected to boost the market during the forecast period. For instance, in June 2020, Emmaus Medcial Inc. has received approval from the Israeli Ministry of Health for the commercial distribution of Endari in Israel. Endari is a Glutamine oral powder used to treat acute complications of sickle diseases in adults and children age 5 years and older. Moreoever, in October 2020, Medunik USa Inc. launched Siklos for pediatric patients with sickle cell diseases. Siklos is a film-coated tablet, that is used to reduce vaso occlusive crisis caused by sickle cell disease.

Market Coverage

  • The market number available for – 2021-2028
  • Base year- 2021
  • Forecast period- 2022-2028

Segment Covered- 

  • By Type
  • By Application

Regions Covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape-   Novartis AG, AstraZeneca Plc., Medunik USA Inc., Bristol-Myers Squibb Co, Emmaus Medical Inc., and more

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Vaso Occlusive Crisis Associated with Sickle Cell disease Market Report Segment

By Type 

  • Crizanlizumab
  • SGD-2083
  • NVX-508
  • PF-04447943 

By Application

  • Hospital
  • Clinic

Global Vaso occlusive crisis associated with sickle cell disease Market Report Segment by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World

  • Latin America 
  • Middle East & Africa


To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/vaso-occlusive-crisis-associated-with-the-sickle-cell-disease-market